|
EP2322545A1
(en)
*
|
1998-12-07 |
2011-05-18 |
Ipsen Pharma |
Analogues of GLP-1
|
|
PL393611A1
(pl)
|
1998-12-07 |
2011-05-09 |
Societe De Conseils De Recherches Et D'applications Scientifiques Sas |
Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków
|
|
CA2417100A1
(en)
*
|
2000-08-02 |
2002-02-07 |
Theratechnologies Inc. |
Modified peptides with increased potency
|
|
US7371721B2
(en)
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
|
US7186683B2
(en)
|
2000-09-18 |
2007-03-06 |
Sanos Bioscience A/S |
Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
|
|
PT1326630E
(pt)
*
|
2000-09-18 |
2008-09-02 |
Sanos Bioscience As |
Utilização de péptidos glp-2
|
|
CA2430934C
(en)
|
2000-12-01 |
2011-06-21 |
Takeda Chemical Industries, Ltd. |
A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
|
|
GB0100196D0
(en)
*
|
2001-01-04 |
2001-02-14 |
Anmat Technology Ltd |
Peptides
|
|
US7576050B2
(en)
*
|
2001-07-31 |
2009-08-18 |
The United States Of America As Represented By The Department Of Health And Human Services |
GLP-1 exendin-4 peptide analogs and uses thereof
|
|
MXPA04003553A
(es)
|
2001-10-18 |
2004-07-22 |
Bristol Myers Squibb Co |
Mimeticos del peptido-1 similares aglucagon humano y su uso en tratamiento de diabetes y condiciones relacionadas.
|
|
US7238671B2
(en)
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
|
US7332819B2
(en)
*
|
2002-01-09 |
2008-02-19 |
Micron Technology, Inc. |
Stacked die in die BGA package
|
|
WO2004029081A2
(en)
*
|
2002-09-25 |
2004-04-08 |
Theratechnologies Inc. |
Modified glp-1 peptides with increased biological potency
|
|
AU2003272970B2
(en)
*
|
2002-10-11 |
2009-05-28 |
Sanwa Kagaku Kenkyusho Co. Ltd. |
GLP-1 derivatives and transmicosal absorption preparations thereof
|
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
|
CN1750842A
(zh)
|
2003-02-19 |
2006-03-22 |
研究及应用科学协会股份有限公司 |
Glp－1的类似物
|
|
WO2004087910A1
(ja)
*
|
2003-03-28 |
2004-10-14 |
National Institute Of Agrobiological Sciences |
組換えタンパク質が高生産された植物貯蔵器官の生産方法及び新規組換えタンパク質
|
|
DE10314610A1
(de)
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
|
ATE541582T1
(de)
|
2003-06-03 |
2012-02-15 |
Novo Nordisk As |
Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
|
|
ATE529126T1
(de)
|
2003-06-03 |
2011-11-15 |
Novo Nordisk As |
Stabilisierte pharmazeutische peptid zusammensetzungen
|
|
US7094800B2
(en)
|
2003-07-25 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Cyanopyrrolidides, process for their preparation and their use as medicaments
|
|
US7094794B2
(en)
|
2003-07-28 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
|
|
DE10335092B3
(de)
|
2003-08-01 |
2005-02-03 |
Aventis Pharma Deutschland Gmbh |
Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
|
|
EP1711523B1
(en)
*
|
2003-12-16 |
2012-10-10 |
Ipsen Pharma |
Analogues of glp-1
|
|
JP2007514752A
(ja)
*
|
2003-12-16 |
2007-06-07 |
ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス |
Ｇｌｐ−１医薬組成物
|
|
JP2007537141A
(ja)
|
2003-12-18 |
2007-12-20 |
ノボ ノルディスク アクティーゼルスカブ |
新規なｇｌｐ−１化合物
|
|
US7538185B2
(en)
*
|
2004-01-08 |
2009-05-26 |
Theratechnologies Inc. |
Glucagon-like peptide-1 analogs with long duration of action
|
|
CN101010339B
(zh)
*
|
2004-07-02 |
2011-11-09 |
布里斯托尔-迈尔斯斯奎布公司 |
人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
|
|
TW200611704A
(en)
*
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
|
JP2008515856A
(ja)
|
2004-10-07 |
2008-05-15 |
ノボ ノルディスク アクティーゼルスカブ |
遅延性ｇｌｐ−１化合物
|
|
EP1799711B1
(en)
|
2004-10-07 |
2012-06-20 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
|
EP1841448A2
(en)
|
2004-12-30 |
2007-10-10 |
Diakine Therapeutics, Inc. |
Pharmaceutical compositions and methods for restoring beta-cell mass and function
|
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
|
WO2006097538A1
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Extended glp-1 compounds
|
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
|
US20070004616A1
(en)
*
|
2005-06-30 |
2007-01-04 |
Roland Cherif-Cheikh |
GLP-1 pharmaceutical compositions
|
|
AU2006265814B2
(en)
*
|
2005-06-30 |
2012-05-10 |
Ipsen Pharma S.A.S. |
GLP-1 pharmaceutical compositions
|
|
CA2628241C
(en)
|
2005-11-07 |
2016-02-02 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
|
ES2495741T3
(es)
|
2006-04-20 |
2014-09-17 |
Amgen, Inc |
Compuestos de GLP-1
|
|
DE602007009377D1
(de)
|
2006-05-30 |
2010-11-04 |
Intarcia Therapeutics Inc |
Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
|
|
CN101563364B
(zh)
*
|
2006-06-23 |
2014-04-02 |
霍夫曼-拉罗奇有限公司 |
促胰岛素肽合成
|
|
GB0612669D0
(en)
*
|
2006-06-27 |
2006-08-09 |
Univ Leeds |
Biomarkers for preeclampsia
|
|
MX2009001043A
(es)
|
2006-08-08 |
2009-02-06 |
Sanofi Aventis |
Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso.
|
|
EP2359808B1
(en)
|
2006-08-09 |
2013-05-22 |
Intarcia Therapeutics, Inc |
Osmotic delivery systems and piston assemblies
|
|
BRPI0716134A2
(pt)
|
2006-09-07 |
2013-09-17 |
Nycomed Gmbh |
tratamento de combinaÇço para diabetes mellitus
|
|
US20100137204A1
(en)
*
|
2006-12-29 |
2010-06-03 |
Zheng Xin Dong |
Glp-1 pharmaceutical compositions
|
|
JP2010523473A
(ja)
*
|
2006-12-29 |
2010-07-15 |
イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ |
Ｇｌｐ−１医薬組成物
|
|
DE102007005045B4
(de)
|
2007-01-26 |
2008-12-18 |
Sanofi-Aventis |
Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
MX2009008241A
(es)
|
2007-02-15 |
2009-10-08 |
Univ Indiana Res & Tech Corp |
Co-agonistas de receptor de glucagon/glp-1.
|
|
AU2008244523B2
(en)
|
2007-04-23 |
2012-02-16 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
EP2190460B1
(en)
|
2007-09-05 |
2014-12-17 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
|
WO2009030738A1
(en)
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
|
CN101842386A
(zh)
|
2007-09-05 |
2010-09-22 |
诺沃-诺迪斯克有限公司 |
截短的glp-1衍生物和它们的治疗用途
|
|
JP2010538069A
(ja)
*
|
2007-09-07 |
2010-12-09 |
イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ |
エキセンディン−４およびエキセンディン−３の類似体
|
|
DK2205624T3
(da)
|
2007-10-27 |
2017-01-02 |
Corden Pharma Colorado Inc |
Insulinotropisk peptidsyntese under anvendelse af faststof- og opløsningsfasekombinationsteknikker
|
|
CA2702289A1
(en)
|
2007-10-30 |
2009-05-07 |
Indiana University Research And Technology Corporation |
Compounds exhibiting glucagon antagonist and glp-1 agonist activity
|
|
DE102007063671A1
(de)
|
2007-11-13 |
2009-06-25 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
|
WO2009074483A2
(en)
*
|
2007-12-11 |
2009-06-18 |
F. Hoffmann-La Roche Ag |
Insulinotropic peptide synthesis using solid and solution phase combination techniques
|
|
DK2240155T3
(da)
|
2008-02-13 |
2012-09-17 |
Intarcia Therapeutics Inc |
Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
|
|
EA019203B9
(ru)
|
2008-06-17 |
2014-03-31 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Коагонисты глюкагонового рецептора/glp-1-рецептора
|
|
WO2010011439A2
(en)
*
|
2008-06-17 |
2010-01-28 |
Indiana University Research And Technology Corporation |
Gip-based mixed agonists for treatment of metabolic disorders and obesity
|
|
CN102131516B
(zh)
|
2008-06-27 |
2016-03-16 |
杜克大学 |
包含弹性蛋白样肽的治疗剂
|
|
BRPI0917000A2
(pt)
|
2008-08-06 |
2016-02-16 |
Novo Nordisk Healthcare Ag |
proteínas conjugadas com eficácia in vivo prolongada
|
|
EP2915538A3
(en)
*
|
2008-08-07 |
2015-10-14 |
Ipsen Pharma S.A.S. |
Truncated analogues of glucose-dependent insulinotropic polypeptide
|
|
BRPI0916890A2
(pt)
*
|
2008-08-07 |
2019-09-24 |
Ipsen Pharma Sas |
composto, composição farmacêutica, métodos para elicitar um efeito agonista, e um efeito antagonista de um receptor de gip, para tratar condições ou doeças, para tratar distúrbios, para tratar ou prevenir causas secundárias de diabete, e para estimular secreção de insulina em um indivíduo, e, uso de um composto
|
|
CN102171243A
(zh)
*
|
2008-08-07 |
2011-08-31 |
益普生制药股份有限公司 |
N-端修饰的葡萄糖依赖性促胰岛素多肽(gip)类似物
|
|
BRPI0917579A2
(pt)
*
|
2008-08-07 |
2016-10-11 |
Ipsen Pharma Sas |
composto, composição farmacêutica, métodos, e, uso de um composto
|
|
TW201012829A
(en)
*
|
2008-09-22 |
2010-04-01 |
Ipsen Mfg Ireland Ltd |
Process for the synthesis of (Aib8,35)hGLP-1(7-36)-NH2
|
|
MA32970B1
(fr)
|
2008-12-15 |
2012-01-02 |
Zealand Pharma As |
Analogues du glucagon
|
|
EA020596B1
(ru)
*
|
2008-12-15 |
2014-12-30 |
Зилэнд Фарма А/С |
Аналоги глюкагона
|
|
WO2010070253A1
(en)
|
2008-12-15 |
2010-06-24 |
Zealand Pharma A/S |
Glucagon analogues
|
|
WO2010070252A1
(en)
|
2008-12-15 |
2010-06-24 |
Zealand Pharma A/S |
Glucagon analogues
|
|
RU2550696C2
(ru)
|
2008-12-19 |
2015-05-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Основанные на амидах пролекарства пептидов глюкагонового надсемейства
|
|
US20100183876A1
(en)
*
|
2008-12-23 |
2010-07-22 |
Hell Andre |
Process for the Preparation of a Peptide Powder Form
|
|
KR20110097889A
(ko)
|
2008-12-23 |
2011-08-31 |
에프. 호프만-라 로슈 아게 |
수집 디바이스 상에서 구동하는 구조화된 수집 절차의 구현, 실행, 데이터 수집, 및 데이터 분석을 위한 관리 방법 및 시스템
|
|
JP5816097B2
(ja)
|
2009-01-22 |
2015-11-18 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
安定な成長ホルモン化合物
|
|
EP2216042A1
(en)
|
2009-02-09 |
2010-08-11 |
Ipsen Pharma S.A.S. |
GLP-1 analogues pharmaceutical compositions
|
|
EP2424888A2
(en)
*
|
2009-05-01 |
2012-03-07 |
F. Hoffmann-La Roche AG |
Insulinotropic peptide synthesis using solid and solution phase combination techniques
|
|
CA2765026A1
(en)
|
2009-06-16 |
2010-12-23 |
Indiana University Research And Technology Corporation |
Gip receptor-active glucagon compounds
|
|
JP6054742B2
(ja)
|
2009-07-13 |
2016-12-27 |
ジーランド ファーマ アクティーゼルスカブ |
アシル化グルカゴン類似体
|
|
CN105963710A
(zh)
|
2009-08-06 |
2016-09-28 |
诺沃—诺迪斯克保健股份有限公司 |
具有延长的体内功效的生长激素
|
|
CA2771278A1
(en)
|
2009-08-26 |
2011-03-03 |
Sanofi |
Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
|
|
LT2462246T
(lt)
|
2009-09-28 |
2017-11-27 |
Intarcia Therapeutics, Inc |
Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
|
|
US20120264685A1
(en)
|
2009-10-22 |
2012-10-18 |
Rajesh Bahekar |
Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
|
|
CN118767116A
(zh)
|
2010-01-22 |
2024-10-15 |
诺沃—诺迪斯克保健股份有限公司 |
体内功效延长的生长激素
|
|
AU2011208620B2
(en)
|
2010-01-22 |
2015-04-16 |
Novo Nordisk Health Care Ag |
Stable growth hormone compounds
|
|
KR20120123443A
(ko)
|
2010-01-27 |
2012-11-08 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
DE102010015123A1
(de)
|
2010-04-16 |
2011-10-20 |
Sanofi-Aventis Deutschland Gmbh |
Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
|
CA2793715A1
(en)
|
2010-04-30 |
2011-11-03 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability
|
|
US8933024B2
(en)
|
2010-06-18 |
2015-01-13 |
Sanofi |
Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
|
|
US20110313131A1
(en)
|
2010-06-21 |
2011-12-22 |
Christelle Carl |
Reversed phase hplc purification of a glp-1 analogue
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
UY33462A
(es)
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
|
AU2011269430A1
(en)
|
2010-06-24 |
2013-01-10 |
Zealand Pharma A/S |
Glucagon analogues
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
RU2600440C3
(ru)
|
2010-12-16 |
2021-12-10 |
Ново Нордиск А/С |
Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
|
|
NZ612297A
(en)
|
2010-12-22 |
2015-10-30 |
Univ Indiana Res & Tech Corp |
Glucagon analogs exhibiting gip receptor activity
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
WO2012120057A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2766349B1
(de)
|
2011-03-08 |
2016-06-01 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
WO2012120055A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
WO2012120058A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
US8828995B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
|
WO2012120054A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
WO2012120051A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US8809324B2
(en)
|
2011-03-08 |
2014-08-19 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
|
EP3225631B1
(en)
|
2011-04-12 |
2019-01-09 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
|
WO2012177444A2
(en)
|
2011-06-22 |
2012-12-27 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
|
WO2012177443A2
(en)
|
2011-06-22 |
2012-12-27 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
|
EP2734239A2
(en)
|
2011-07-18 |
2014-05-28 |
Arts Biologics A/S |
Long acting luteinizing hormone (lh) compound
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
PT2827845T
(pt)
|
2012-03-22 |
2019-03-29 |
Novo Nordisk As |
Composições compreendendo um agente de entrega e sua preparação
|
|
EP3488857B9
(en)
|
2012-03-22 |
2023-10-04 |
Novo Nordisk A/S |
Compositions of glp-1 peptides and preparation thereof
|
|
NZ702333A
(en)
|
2012-05-03 |
2017-06-30 |
Zealand Pharma As |
Gip-glp-1 dual agonist compounds and methods
|
|
CN107739409A
(zh)
|
2012-05-18 |
2018-02-27 |
爱德迪安（北京）生物技术有限公司 |
用于糖尿病治疗的蛋白、蛋白缀合物及其应用
|
|
JP6517690B2
(ja)
|
2012-06-20 |
2019-05-22 |
ノヴォ ノルディスク アー／エス |
ペプチド及び送達剤を含む錠剤製剤
|
|
WO2014010586A1
(ja)
|
2012-07-10 |
2014-01-16 |
武田薬品工業株式会社 |
注射用製剤
|
|
KR101848303B1
(ko)
|
2012-07-10 |
2018-04-13 |
삼성전자주식회사 |
전력 전송을 제어하기 위한 방법 및 이를 위한 전력 송신기
|
|
DK2875043T3
(en)
|
2012-07-23 |
2017-03-27 |
Zealand Pharma As |
glucagon
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
IN2015DN03795A
(pt)
|
2012-10-24 |
2015-10-02 |
Inserm Inst Nat De La Santé Et De La Rech Médicale |
|
|
WO2014077801A1
(en)
|
2012-11-13 |
2014-05-22 |
Ipsen Pharma S.A.S. |
Purification process for preparing highly pure taspoglutide
|
|
CN104936610A
(zh)
|
2012-11-13 |
2015-09-23 |
益普生制药股份有限公司 |
Glp-1类似物的纯化方法
|
|
EP2981282B1
(en)
|
2013-04-05 |
2020-11-04 |
Novo Nordisk Health Care AG |
Growth hormone compound formulation
|
|
WO2014209886A1
(en)
|
2013-06-23 |
2014-12-31 |
Wisconsin Alumni Research Foundation |
Alpha/beta-polypeptide analogs of glucagon-like peptid-1
|
|
CN103536907B
(zh)
*
|
2013-07-18 |
2015-10-21 |
上海交通大学医学院附属瑞金医院 |
利拉鲁肽在骨质疏松治疗药物中的应用
|
|
UA122767C2
(uk)
|
2013-10-17 |
2021-01-06 |
Зіленд Фарма А/С |
Ацильований аналог глюкагону
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
BR112016009889B1
(pt)
|
2013-11-06 |
2023-11-28 |
Zealand Pharma A/S |
Análogo do gip, composição farmacêutica compreendendo um análogo do gip, ou um sal farmaceuticamente aceitável do mesmo, e seu uso
|
|
CN105829339B
(zh)
|
2013-11-06 |
2021-03-12 |
西兰制药公司 |
胰高血糖素-glp-1-gip三重激动剂化合物
|
|
CN105934257B
(zh)
|
2013-12-06 |
2020-10-09 |
韩捷 |
用于含氮和羟基的药物的生物可逆引入基团
|
|
WO2015086686A2
(en)
*
|
2013-12-13 |
2015-06-18 |
Medimmune Limited |
Protease resistant peptides
|
|
EP3129041B1
(en)
|
2014-04-07 |
2019-06-12 |
Novo Nordisk A/S |
Double-acylated glp-1 compounds
|
|
WO2016034186A1
(en)
|
2014-09-05 |
2016-03-10 |
University Of Copenhagen |
Gip peptide analogues
|
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
|
US10253078B2
(en)
|
2014-10-29 |
2019-04-09 |
Zealand Pharma A/S |
GIP agonist compounds and methods
|
|
EP3273981B1
(en)
|
2015-03-24 |
2020-04-29 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Method and pharmaceutical composition for use in the treatment of diabetes
|
|
KR20170137198A
(ko)
|
2015-04-16 |
2017-12-12 |
질랜드 파마 에이/에스 |
아실화된 글루카곤 유사체
|
|
US10925639B2
(en)
|
2015-06-03 |
2021-02-23 |
Intarcia Therapeutics, Inc. |
Implant placement and removal systems
|
|
CN106554409B
(zh)
*
|
2015-09-30 |
2020-04-07 |
天津药物研究院有限公司 |
一种长效胰高血糖素样肽-1类似物及其应用
|
|
EP3458084B1
(en)
|
2016-05-16 |
2020-04-01 |
Intarcia Therapeutics, Inc |
Glucagon-receptor selective polypeptides and methods of use thereof
|
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
|
KR20190104039A
(ko)
|
2017-01-03 |
2019-09-05 |
인타르시아 세라퓨틱스 인코포레이티드 |
Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
|
|
WO2018220123A1
(en)
|
2017-05-31 |
2018-12-06 |
University Of Copenhagen |
Long-acting gip peptide analogues
|
|
BR112020014624A2
(pt)
|
2018-02-02 |
2020-12-08 |
Novo Nordisk A/S |
Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
|
|
CA3094820A1
(en)
*
|
2018-03-23 |
2019-09-26 |
Carmot Therapeutics, Inc. |
Modulators of g-protein coupled receptors
|
|
MX2020010505A
(es)
|
2018-04-05 |
2021-01-15 |
Sun Pharmaceutical Ind Ltd |
Analogos novedosos de glp-1.
|
|
WO2019200594A1
(zh)
|
2018-04-19 |
2019-10-24 |
杭州先为达生物科技有限公司 |
酰化的glp-1衍生物
|
|
AR116632A1
(es)
|
2018-10-11 |
2021-05-26 |
Intarcia Therapeutics Inc |
Polipéptidos análogos de la amilina humana y sus métodos de uso
|
|
CN109400695B
(zh)
|
2018-10-31 |
2020-06-30 |
中南大学湘雅医院 |
一种多肽的修饰方法及应用
|
|
CA3121043A1
(en)
|
2018-12-03 |
2020-06-11 |
Antag Therapeutics Aps |
Modified gip peptide analogues
|
|
EP4281039A2
(en)
|
2021-01-25 |
2023-11-29 |
Mylan Ireland Limited |
Pharmaceutical glp peptide compositions and methods of preparation thereof
|
|
CN115850438B
(zh)
*
|
2021-12-28 |
2023-05-12 |
北京惠之衡生物科技有限公司 |
一种长效glp-1衍生物
|
|
TW202421654A
(zh)
|
2022-09-28 |
2024-06-01 |
丹麥商西蘭製藥公司 |
治療肥胖之方法
|
|
WO2024123812A1
(en)
|
2022-12-05 |
2024-06-13 |
Shattuck Labs, Inc. |
Fusion proteins for the treatment of cardiometabolic diseases
|